Longeveron reports H1 2024 net loss down 27%; Lomecel-B gets RMAT/Fast Track for Alzheimer's

Longeveron Inc.

2024-Q2 EPS reported -$3.54 revenue$1,016,000

H1 2024 net loss $7.5M (down 27% YoY from $10.3M); revenue $1.0M (up 105% YoY from $0.5M).
Cash $12.4M at June 30; July capital raises gross $15.3M (Registered Direct $9.0M, warrant exercises $6.3M); runway through Q4 2025.
FDA granted RMAT and Fast Track for Lomecel-B in mild Alzheimer's after positive Phase 2a CLEAR MIND data at AAIC.
Phase 2b HLHS trial (ELPIS II) at 70% enrollment; targeting completion by end of 2024.
Launched CDMO business; expects $4-5M annual revenue once fully operational.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.